静电和振荡电场如何在分解阿尔茨海默氏症和其他老年斑块方面发挥作用?
Surajit Kalita1, Hagai Bergman2, Kshatresh Dutta Dubey3
1Institute of Chemistry, The Hebrew University of Jerusalem, Edmond J. Safra Campus, Givat Ram, Jerusalem 9190401, Israel.
Journal of the American Chemical Society
|February 3, 2023
概括
定向外部电场 (OEEF) 可以预防和分解β-粉样斑块,为阿尔茨海默病和相关的神经退行性疾病提供潜在的新治疗方法.
科学领域:
- 神经科学
- 生物物理
- 计算生物学
背景情况:
- 阿尔茨海默病是一种常见的神经退行性疾病,其特征是β-粉样斑块的积累.
- 在其他神经退行性疾病中也观察到类似的斑块病理.
- 这些斑块的分解是治疗的目标.
研究的目的:
- 研究静态和振荡导向外部电场 (OEEF) 对β-粉样蛋白斑块聚合和分解的影响.
- 了解斑块分解背后的机制和堆积物在现场后的去除命运.
- 将OEEF效应与TTFields和深度大脑刺激 (DBS) 等现有疗法进行比较.
主要方法:
- 使用了经典的分子动力学模拟.
- 在静态和振荡的OEEF下,模拟分析了β-粉样蛋白斑块的行为.
- 这项研究研究了自发聚合,预防,分解和现场后效应.
主要成果:
- OEEF被证明可以防止和分解β-粉样聚合物.
- 振荡的OEEF显示了β-粉样聚合物的不可逆性分解.
- 对于静态和振荡的OEEF观察到不同的分解机制.
结论:
- OEEF对破坏β-粉样质斑块,这是阿尔茨海默病的标志性表现有前途.
- 振荡式OEEF可以提供更有效,不可逆转的分解方法.
- 这些发现为开发与斑块相关的神经退行性疾病的新疗法提供了洞察力.
相关概念视频
Amyloid Fibrils
9.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Overview
594
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
594
Alzheimer's Disease: Treatment
237
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
237


